Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Frontiers in Oncology, 2019 The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the ...
Danielle Golub +2 more
exaly +4 more sources
Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH) [PDF]
PLoS Genetics, 2017 DJ-1 is one of the causative genes for early onset familiar Parkinson's disease (PD) and is also considered to influence the pathogenesis of sporadic PD. DJ-1 has various physiological functions which converge on controlling intracellular reactive oxygen
Woongchang Yoon +2 more
exaly +3 more sources
Physiological regulation of isocitrate dehydrogenase and the role of 2-oxoglutarate in Prochlorococcus sp. strain PCC 9511. [PDF]
PLoS ONE, 2014 The enzyme isocitrate dehydrogenase (ICDH; EC 1.1.1.42) catalyzes the oxidative decarboxylation of isocitrate, to produce 2-oxoglutarate. The incompleteness of the tricarboxylic acids cycle in marine cyanobacteria confers a special importance to ...
María Agustina Domínguez-Martín +5 more
doaj +5 more sources
Isocitrate dehydrogenase mutations in gliomas. [PDF]
Neuro-Oncology, 2016 Over the last decade, extraordinary progress has been made in elucidating the underlying genetic causes of gliomas. In 2008, our understanding of glioma genetics was revolutionized when mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) were ...
Matthew S. Waitkus, B. Diplas, Hai Yan
semanticscholar +4 more sources
Purification of yeast isocitrate dehydrogenase [PDF]
Biochemical Journal, 1972 The NAD-linked isocitrate dehydrogenase from baker's yeast was purified to homogeneity (as judged by gel filtration and polyacrylamide-gel electrophoresis) with an overall yield of 50% by using dilute solutions of the allosteric effector (AMP) to elute the enzyme specifically from CM-cellulose.
John Illingworth
openalex +4 more sources
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Biomarker Research, 2019 Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and ...
Xiaoyan Liu, Yuping Gong
doaj +2 more sources
Isocitrate dehydrogenase mutations in myeloid malignancies [PDF]
Leukemia, 2016 Alterations to genes involved in cellular metabolism and epigenetic regulation are implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate dehydrogenase (IDH) genes are detected in approximately 20% of adult patients with acute myeloid leukemia (AML) and 5% of adults with myelodysplastic syndromes (MDS).
B. Medeiros +5 more
semanticscholar +5 more sources
Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
Frontiers in Oncology, 2019 Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an important role in energy metabolism. In recent years, it has been found that IDH mutations are closely related to the occurrence and development of glioma, and ...
Juan Huang, Yong Luo, Beatriz Soriano
exaly +2 more sources
Mitochondrial Isocitrate Dehydrogenases from Yeast [PDF]
Journal of Biological Chemistry, 1966 Abstract A polarographic technique suitable for kinetic studies of either isolated or bound pyridine nucleotide-linked dehydrogenases was used to investigate the isocitrate dehydrogenases of yeast mitochondria. Intact mitochondria were found to contain both triphosphopyridine nucleotide- and diphosphopyridine nucleotide-linked isocitrate dehydrogenases
Carl Bernofsky, Merton Utter
openalex +3 more sources
A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases [PDF]
Frontiers in PharmacologyBackground and objectivesIsocitrate dehydrogenase (IDH) inhibitor drugs (Enasidenib, Ivosidenib) restore normal metabolism and epigenetic regulation in cells, offering a precision-targeted therapeutic option for acute myeloid leukemia (AML) patients with
Mengmeng Peng +11 more
doaj +2 more sources